Trial Profile
A Phase II Study of Durvalumab in Patients With Mismatch Repair Deficient or POLE Mutated Metastatic Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Colon cancer; Rectal cancer
- Focus Therapeutic Use
- 15 Dec 2022 Planned End Date changed from 31 May 2022 to 31 Dec 2023.
- 15 Dec 2022 Planned primary completion date changed from 31 Mar 2022 to 30 Jun 2023.
- 02 May 2022 Results evaluate the clinical efficacy of durvalumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) or polymerase epsilon mutated metastatic or unresectable colorectal cancer, published in the International Journal of Cancer